- Overcoming the Anxiety Associated with Breast Cancer Screening
- Paying Women to Have Mammograms Presents Ethical Problems
- Acupuncture Treatments Benefit Breast Cancer Survivors
- Download a Free e-Book to Reduce Your Breast Cancer Risk
- Accurately Assessing Breast Cancer Risk
- Biomarker Holds Promise for Treating Breast and Prostate Cancers
- Smoking Lowers Breast Cancer Survival Rates
- Understanding the Link Between Phthlate Exposure and Breast Cancer Risk
- Young Women with Breast Cancer Have Unique Needs
- Texts Boost Breast Cancer Screening Numbers
Research Clarifies How HIV Interacts With Immune System
Understanding how the virus evades the immune system after infection with HIV has major implications for preventing the disease. New research has examined how antibodies and the virus interact, which may help scientists develop an effective vaccine in the future.
Latest insights into immunity to HIV could help to develop a vaccine to build antibodies’ defences against the disease, a University of Melbourne, Australia study has found.
By investigating the action of the human antibodies called ADCC, in people with HIV, researchers were able to identify that the virus evolves to evade or ‘escape’ the antibodies.
Professor Stephen Kent of the University of Melbourne and one of the senior authors on the paper said ADCC antibodies have been strongly implicated in protection from HIV in several vaccine trials but their action was poorly understood.
“These results show what a slippery customer the HIV virus is, but also shows that these ADCC antibodies are really forcing the virus into changing, in ways that cause it to be weaker,” he said.
“It also implies that if good ADCC antibodies were available prior to infection, via a vaccine, we might be able to stop the virus taking hold. This is the holy grail.”
The group at the University of Melbourne’s Department of Microbiology and Immunology analysed blood samples of people with HIV and found their virus had evolved to evade or ‘escape’ the ADCC antibodies against HIV they are making to try to control their virus.
The team led by Dr Ivan Stratov and Professor Kent employed a novel technology developed in their laboratory to find where ADCC antibodies were attacking the virus. They then looked at how the sequence of the virus had mutated over time to avoid the immune response.
“There is an urgent need to identify effective immunity to HIV and our studies suggest ADCC responses supply significant immune pressure on the virus,” Dr Ivan Stratov, a clinician and researcher said.
The group is now working on designing HIV vaccines to induce ADCC antibodies that make it more difficult for the virus to escape.
The work was published in the prestigious international journal PNAS.
Reference: University of Melbourne